Skip to main content
Bonesupport Holding logo

Bonesupport Holding — Investor Relations & Filings

Ticker · BONEX ISIN · SE0009858152 LEI · 549300COLY053IGTLD63 ST Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2019-02-13 Regulatory Filings
Country SE Sweden
Listing ST BONEX

About Bonesupport Holding

https://www.bonesupport.com/en-eu/

Bonesupport Holding is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. Its core product platform, CERAMENT®, is an innovative range of osteoconductive and drug-eluting products designed to heal bone defects. A key characteristic of CERAMENT® is its ability to remodel into the patient's own host bone, typically within six to twelve months. The products are used to treat bone voids and defects arising from trauma, infection, disease, or related surgical procedures. The radiopaque nature of the material allows for visualization during and after surgery.

Recent filings

Filing Released Lang Actions
Rättelse av fel Q3(18) rapport
Regulatory Filings Classification · 1% confidence The document is titled "Rättelse av fel Q3(18) rapport" (Correction of error Q3(18) report) and explicitly states that a previously published Q3 2018 report contained an error regarding gross profit and net result. It details the correction and provides revised figures for Q3 2018 and the first nine months of 2018. This is a specific announcement correcting financial data previously released. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a simple Earnings Release (ER) highlighting new results. Since it is a specific correction related to financial reporting, it fits best under the general category for regulatory announcements that don't fit elsewhere, or potentially a specific type of financial update. Given the options, it is a specific regulatory disclosure concerning financial figures, but since there is no 'Financial Correction' code, and it is a formal announcement of a correction mandated by regulations (EU Market Abuse Regulation mentioned), the most appropriate general category for specific, non-standard regulatory disclosures is 'Regulatory Filings' (RNS). However, because the core content is a correction to a quarterly financial report, and it is not a full report itself, it is a specific type of regulatory disclosure. If we consider the nature of the correction (financial results), it is a specific regulatory filing. Given the options, RNS is the best fit as a miscellaneous regulatory filing, although it is highly specific. Alternatively, since it corrects a prior financial report, it is a regulatory disclosure. I will classify it as RNS as it is a specific regulatory announcement that doesn't match the other detailed financial codes (like ER or IR). The document length is short (2250 chars), suggesting it's an announcement rather than the full corrected report.
2019-02-13 Swedish
Correction of error Q3 (18) report
Regulatory Filings Classification · 1% confidence The document is titled "Correction of error Q3 (18) report" and details a correction to previously published financial figures (gross profit, margin, net result) for the third quarter of 2018. This is a specific announcement correcting financial data, not the full periodic report itself (which would be an IR). It is not a general earnings release (ER) as it is a correction, nor is it a management discussion (MDA) which usually accompanies the full report. Since it is a specific announcement regarding financial results correction, and it is short and focused on a specific regulatory disclosure obligation (EU Market Abuse Regulation), it fits best under the general 'Regulatory Filings' category (RNS) as a specific, non-standard financial disclosure, or potentially a specialized 'Audit Report / Information' (AR) if the correction is treated as an internal review outcome, but RNS is the safer fallback for specific, non-standard regulatory disclosures that aren't standard ER/IR/10-K/etc. Given the nature of correcting prior financial reporting under MAR obligations, RNS is the most appropriate general regulatory filing category when a more specific correction code is unavailable.
2019-02-13 English
BONESUPPORT publicerar preklinisk studie som belyser CERAMENTs unika egenskaper för benåterbildning vid större bendefekter
Regulatory Filings Classification · 1% confidence The document is a press release from BONESUPPORT announcing the publication of preclinical study results regarding their product CERAMENT in a medical journal (APMIS). It details the study's findings, mentions key personnel, and provides a link to the publication. This type of announcement, which communicates a specific, non-financial, operational or scientific update (like a study publication), does not fit neatly into the primary financial filing categories (10-K, ER, IR, etc.). Since it is an announcement about a scientific/regulatory development and not a standard financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it serves as a general regulatory/operational disclosure to the market.
2019-02-08 Swedish
BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects
Regulatory Filings Classification · 1% confidence The document is a press release dated February 8, 2019, announcing the publication of a pre-clinical study regarding their product CERAMENT in the APMIS journal. It details the study's findings, names the authors, and provides a link to the publication. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a general announcement about the release of a major report (RPA). It is a specific announcement concerning scientific/research findings related to the company's product, which falls under general corporate or investor news. Since there is no specific category for 'Scientific Publication Announcement,' and it is a formal announcement of new information, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard announcements, or potentially 'LTR' if the study were regulatory in nature, but here it seems like positive research news. Given the options, RNS is the best fit for a press release announcing a published study.
2019-02-08 English
BONESUPPORT and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting
Report Publication Announcement Classification · 1% confidence The document announces that BONESUPPORT and Lund University will present research findings at the Orthopaedic Research Society (ORS) 2019 Annual Meeting. It details the specific oral and poster presentations, including titles and author affiliations. This content is characteristic of materials shared or presented at a scientific or annual general meeting, rather than a formal regulatory filing (like 10-K, ER, or IR) or a general announcement of a report release (RPA). Since the content is directly related to presentations at an Annual Meeting (ORS 2019 Annual Meeting), the most appropriate classification is AGM-R (AGM Information), as it covers presentations and materials shared during a significant annual gathering, even if it is a scientific meeting rather than a shareholder AGM, given the available options.
2019-02-01 English
BONESUPPORT presenterar tillsammans med Lunds Universitet på årets Orthopaedic Research Society möte 2019
Regulatory Filings Classification · 1% confidence The document is a press release from BONESUPPORT announcing that they will be presenting research findings at the Orthopaedic Research Society (ORS) meeting in February 2019. It details the specific oral and poster presentations, names the researchers, and provides context about the research collaboration with Lund University. This type of announcement, detailing participation in an external scientific/industry event, does not fit the definitions for 10-K, ER, IR, or standard regulatory filings. It is an announcement about company activity and research dissemination, which is often categorized as Investor Information or a general Regulatory Filing (RNS) if no better fit exists. Since it is an announcement about participation in a scientific meeting rather than a formal financial report or management change, and it is not a proxy statement (DEF 14A) or a dividend notice (DIV), the most appropriate general category for this type of corporate/research update that doesn't fit the specific financial/governance codes is Regulatory Filings (RNS), as it is a public disclosure of corporate activity. Given the context of presenting research, it could also be seen as Investor Information, but RNS is the standard fallback for non-standard press releases.
2019-02-01 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.